Asymptomatic primary hyperparathyroidism: A commentary on the revised guidelines

Endocrine Practice

Volumn 15, Issue 5, 2009, Pages 494-498

  Khan, Aliya A ^a   Bilezikian, John P ^b   Potts Jr , John T ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b Columbia University ^*  (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CINACALCET; CREATININE; PARATHYROID HORMONE; VITAMIN D;

AGE DISTRIBUTION; BONE DENSITOMETRY; BONE DENSITY; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CARDIOVASCULAR EFFECT; COGNITION; CORTICAL BONE; CREATININE CLEARANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HIP; HUMAN; HYPERCALCEMIA; KIDNEY FUNCTION; NEPHROLITHIASIS; NEUROPSYCHOLOGY; NOTE; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; SYMPTOMATOLOGY; URINE; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; ARTICLE; BLOOD; METABOLISM; PATHOLOGY;

GUIDELINES AS TOPIC; HUMANS; HYPERPARATHYROIDISM, PRIMARY;

EID: 70449700405     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09162.CO     Document Type: Note

References (22)

1. Khan AA, Bilezikian JP, Potts JT Jr (Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism). The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab. 2009;94:333-334.
2. Bilezikian JP, Khan AA, Potts JT Jr (Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism). Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009;94:335-339.
3. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:340-350.
4. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:351-365.
5. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:366-372.
6. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:373-381.
7. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001-3005.
8. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;4:283-291.
9. Khosla S, Melton LJ III. Fracture risk in primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2): N103-N107.
10. Charopoulos I, Tournis S, Trovas G, et al. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab. 2006;91:1748-1753.
11. Dempster DW, Müller R, Zhou H, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41:19-24.
12. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res. 2002;17(suppl 2):N87-N94.
13. Silverberg SJ, Brown I, Bilezikian JP. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med. 2002;113:681-684.
14. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005;90:2122-2126.
15. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized, controlled clinical trial of surgery versus no surgery in mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004;89:5415-5422.
16. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92:1687-1692.
17. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92:3114-3121.
18. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Actions of parathyroid hormone on the vasculature and cardiovascular system. In: Bilezikian JP, Raisz LG, Martin TJ, eds. Principles of Bone Biology. 3rd ed. San Diego, CA: Elsevier/Academic Press, 2008: 657-663.
19. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:3326-3330.
20. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15-years. J Clin Endocrinol Metab. 2008;93:3462-3470.
21. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325.
22. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135-141.